What do systematic reviews say?

Abundant water intake vs no treatment

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Abundant water intake vs no treatment

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sleeping in darkness vs no treatment

It is very uncertain whether sleeping in darkness changes improvement in frequency of vertigo compared with no treatment (very low certainty).

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  RR 1.47 [1.15, 1.89]
  1 study · 130 participants
  Very low

Sleeping in darkness vs no treatment

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sleeping in darkness vs no treatment

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Specially processed cereals vs placebo

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Specially processed cereals vs placebo

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Specially processed cereals vs placebo

The review found no eligible studies for this question.

• Lifestyle and dietary interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intratympanic corticosteroids vs placebo/no treatment

Intratympanic corticosteroids showed no clear difference in improvement in vertigo frequency compared with placebo/no treatment (low certainty).

• Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
  RR 1 [0.92, 1.1]
  2 studies · 60 participants
  Low
• Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
  RR 1.03 [0.87, 1.23]
  2 studies · 58 participants
  Low

Intratympanic corticosteroids vs placebo/no treatment

• Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Very low

Intratympanic corticosteroids vs placebo/no treatment

• Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 472 participants
  Low
• Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Very low
• Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 18 participants
  Very low

Intratympanic corticosteroids vs placebo/no treatment

It is very uncertain whether intratympanic corticosteroids changes serious adverse events compared with placebo/no treatment (very low certainty).

• Intratympanic corticosteroids for Ménière’s disease 2023 · Cochrane Headline outcomes only
  RR 0.64 [0.22, 1.85]
  4 studies · 500 participants
  Very low

Intratympanic gentamicin vs no treatment/placebo

It is very uncertain whether intratympanic gentamicin changes improvement in vertigo frequency compared with no treatment/placebo (very low certainty).

• Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
  RR 33 [2.15, 507]
  1 study · 32 participants
  Very low
• Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
  RR 1.63 [0.98, 2.69]
  1 study · 22 participants
  Very low

Intratympanic gentamicin vs no treatment/placebo

• Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low
• Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low

Intratympanic gentamicin vs no treatment/placebo

• Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Intratympanic gentamicin vs no treatment/placebo

The review found no eligible studies for this question.

• Intratympanic gentamicin for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Positive pressure therapy vs placebo

Positive pressure therapy showed no clear difference in improvement in vertigo frequency compared with placebo (low certainty).

• Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
  RR 1.19 [0.82, 1.71]
  1 study · 77 participants
  Low

Positive pressure therapy vs placebo

• Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 68 participants
  Very low

Positive pressure therapy vs placebo

• Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 202 participants
  Very low

Positive pressure therapy vs placebo

The review found no eligible studies for this question.

• Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found